These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 11786670)

  • 1. Importance of individual response in symptom score evaluation.
    Desgrandchamps F
    Eur Urol; 2001; 40 Suppl 3():2-7. PubMed ID: 11786670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of tamsulosin hydrochloride on lower urinary tract symptoms and quality of life in patients with benign prostatic hyperplasia. Evaluation using bother score.
    Yoshida M; Sugiyama Y; Masunaga K; Maeda Y; Satoji Y; Nagata T; Inadome A
    Drugs Today (Barc); 2007 Jun; 43 Suppl B():1-7. PubMed ID: 17612712
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microwave thermotherapy for benign prostatic hyperplasia.
    Hoffman RM; Monga M; Elliot SP; Macdonald R; Wilt TJ
    Cochrane Database Syst Rev; 2007 Oct; (4):CD004135. PubMed ID: 17943811
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of prostate artery embolization for benign prostatic hyperplasia: an observational study and propensity-matched comparison with transurethral resection of the prostate (the UK-ROPE study).
    Ray AF; Powell J; Speakman MJ; Longford NT; DasGupta R; Bryant T; Modi S; Dyer J; Harris M; Carolan-Rees G; Hacking N
    BJU Int; 2018 Aug; 122(2):270-282. PubMed ID: 29645352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation of the International Prostate Symptom Score bother question with the Benign Prostatic Hyperplasia Impact Index in a clinical practice setting.
    O'Leary MP; Wei JT; Roehrborn CG; Miner M;
    BJU Int; 2008 Jun; 101(12):1531-5. PubMed ID: 18445080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of a hexanic extract of Serenoa repens (Permixon
    Vela-Navarrete R; Alcaraz A; Rodríguez-Antolín A; Miñana López B; Fernández-Gómez JM; Angulo JC; Castro Díaz D; Romero-Otero J; Brenes FJ; Carballido J; Molero García JM; Fernández-Pro Ledesma A; Cózar Olmos JM; Manasanch Dalmau J; Subirana Cachinero I; Herdman M; Ficarra V
    BJU Int; 2018 Dec; 122(6):1049-1065. PubMed ID: 29694707
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early improvement of storage or voiding symptoms by tadalafil predicts treatment outcomes in patients with lower urinary tract symptoms from benign prostatic hyperplasia.
    Yokoyama O; Ozeki A; Suzuki N; Murakami M
    Int J Urol; 2018 Mar; 25(3):240-245. PubMed ID: 29094398
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Individual patient data from registrational trials of silodosin in the treatment of non-neurogenic male lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH): subgroup analyses of efficacy and safety data.
    Novara G; Chapple CR; Montorsi F
    BJU Int; 2015 May; 115(5):802-14. PubMed ID: 25130493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quality-of-life assessment in patients with benign prostatic hyperplasia: effects of various interventions.
    Batista-Miranda JE; Diez MD; Bertrán PA; Villavicencio H
    Pharmacoeconomics; 2001; 19(11):1079-90. PubMed ID: 11735675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of tadalafil on male lower urinary tract symptoms: an integrated analysis of storage and voiding international prostate symptom subscores from four randomised controlled trials.
    Chapple CR; Roehrborn CG; McVary K; Ilo D; Henneges C; Viktrup L
    Eur Urol; 2015 Jan; 67(1):114-122. PubMed ID: 25301757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Quality of life assessment of the male with benign prostate hypertrophy].
    Nekić VC; Tiljak H; Petricek G; Soldo D; Nekić G; Buljan N
    Acta Med Croatica; 2007 Feb; 61(1):49-55. PubMed ID: 17593641
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quality of life and sexuality: methodological aspects.
    O'Leary MP
    Eur Urol; 2001; 40 Suppl 3():13-8. PubMed ID: 11786672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia.
    Garimella PS; Fink HA; Macdonald R; Wilt TJ
    Cochrane Database Syst Rev; 2009 Oct; (4):CD007360. PubMed ID: 19821408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Interpretation of results of clinical trials in benign prostatic hyperplasia].
    Millán Rodríguez F; Rodríguez Vallejo JM; Carballido Rodríguez J
    Actas Urol Esp; 2002 Jan; 26(1):4-14. PubMed ID: 11899738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can we use baseline characteristics to assess which men with moderately symptomatic benign prostatic hyperplasia at risk of progression will benefit from treatment? A post hoc analysis of data from the 2-year CONDUCT study.
    Roehrborn CG; Oyarzabal Perez I; Roos EP; Calomfirescu N; Brotherton B; Palacios JM; Vasylyev A; Manyak MJ
    World J Urol; 2017 Mar; 35(3):421-427. PubMed ID: 27334136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of Demography and Personality on Patient Choice of Treatment in Symptomatic Benign Prostate Hyperplasia.
    Kesari D; Benjamin J; Podberezsky A; Yulish E; Lobik L; Sumalinsky D; Cytron S
    Isr Med Assoc J; 2015 Jul; 17(7):433-6. PubMed ID: 26357720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of the International Prostate Symptom Score (IPSS) in Chinese male patients with benign prostatic hyperplasia.
    Wong CK; Choi EP; Chan SW; Tsu JH; Fan CW; Chu PS; Cheung FK; Ma WK; Mah ISF; Yip SK; Hou SS; So HS; Lam CK
    Aging Male; 2017 Dec; 20(4):241-249. PubMed ID: 28787255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The visual prostate symptom score is a simple tool to identify and follow up in general practice patients with lower urinary tract symptoms associated with benign prostatic hyperplasia (a study with 1359 patients).
    Descazeaud A; Coloby P; Taille A; Karsenty G; Kouri G; Rossi D; Carrois F; Zerbib M
    Presse Med; 2018; 47(7-8 Pt 1):e91-e98. PubMed ID: 30075950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Factors determining treatment strategies for patients with benign prostatic hyperplasia. The DUO study].
    Fourcade RO; Picot MC; Gaudin AF; Texier N; Slama A
    Presse Med; 2007 May; 36(5 Pt 1):755-63. PubMed ID: 17329070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quality of life assessment for evaluating benign prostatic hyperplasia treatments. An example of using a condition-specific index.
    Fowler FJ; Barry MJ
    Eur Urol; 1993; 24 Suppl 1():24-7. PubMed ID: 7687555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.